Investigating Rosuvastatin DDI Prediction
Rosuvastatin is used in the treatment of dyslipidemia. The drug transporter BCRP (breast cancer resistant protein) has been identified as the rate limiting barrier to rosuvastatin absorption.
In this poster, we focus on:
- whether estrone 3-sulfate can be applied as a surrogate in vitro BCRP probe substrate for predicting rosuvastatin DDI
- a comparison of BCRP inhibition assessment using rosuvastatin or estrone 3-sulfate as probe substrate for six established BCRP inhibitors for which a clinical DDI with rosuvastatin has been characterised
Read our poster to learn more about our research!
Sounds interesting?
Enter your details below to continue reading…
